Nong Yang

机构：Central South University, Chinese Academy of Medical Sciences & Peking Union Medical College, Second People Hospital of Hunan, Hunan Cancer Hospital

发表论文 71 篇 · 总被引 3318 次 · h-index 18

代表论文

• Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial (2024 · Journal of Thoracic Oncology · 被引 146)
• Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial (2024 · Nature Medicine · 被引 45)
• RETRACTED ARTICLE: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial (2026 · Nature Medicine · 被引 23)
• Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial (2026 · The Lancet · 被引 20)
• Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial (2026 · Nature Medicine · 被引 16)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)